Key facts
- It has raised $3.5M; the latest was Seed Round ($2.3M) in Jul 2025.
- Notable investors include Almi Invest, Nordic Science Investments, STUNS Life Science.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Pixl Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Pixl Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pixl Bio
Operator of an induced pluripotent stem cell biology and artificial intelligence phenomics platform intended to generate reproducible data for drug development. The company's platform offers disease-relevant cell models combined with image-based analysis of cellular morphology, enabling biopharmaceutical researchers to assess drug response, toxicity and mechanism of action.
- Sector
- Healthcare
- HQ
- Uppsala, Sweden
- Founded
- 2021
- Employees
- 18
- Website
- pixl.bio/
- Ownership
- Privately Held (backing)
Pixl Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pixl Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pixl Bio in its N-PORT filings yet. We sweep new filings monthly.